Business Wire

Tacton Acquires Variantum and Serenytics to Deliver the Most Complete End-to-End Platform for Complex Manufacturers

7.10.2025 09:00:00 EEST | Business Wire | Press release

Share

Tacton, the global leader in CPQ Buyer Engagement solutions for complex manufacturers, announced today the acquisition of Variantum, a Finnish software company specializing in Configuration Lifecycle Management (CLM), Configurable Order Fulfillment (COF), and Configured Installed Base (CIB). The move expands Tacton’s platform beyond Configure, Price, Quote (CPQ) into engineering, order fulfillment, and service, creating the most complete end-to-end platform for manufacturers of configured products.

Tacton has also acquired Serenytics, a French-based analytics provider. With Serenytics embedded, the platform now delivers near real-time enterprise insights & analytics into buyer behavior, product performance and lifecycle profitability giving manufactures a single source of truth to make every decision accurate, profitable and data-driven.

Closing the Gaps in Manufacturing

Manufacturers of complex, customized equipment have long been held back by disconnected processes and siloed data. Sales, engineering, and production often operate in separate systems with conflicting information that results in quoting errors, costly engineering handovers, margin erosion, and late deliveries.

“With Variantum, we are solving one of manufacturing’s most critical challenges: connecting what is sold with what is engineered, built, and delivered,” said Klaus Andersen, CEO of Tacton. “For the first time, manufacturers can unify the entire lifecycle within one platform, ensuring accuracy, speed, and profitability from start to finish.”

Connecting the Lifecycle from Design to Delivery

Founded in 2005 in Espoo, Finland, Variantum brings deep expertise in lifecycle-wide configuration. Its products help manufacturers:

  • Ensure lifecycle integrity with a single source of truth for configurability across engineering, sales, and production with Configuration Lifecycle Management (CLM).
  • Deliver profitably with automated, order-specific manufacturing BOMs, optimized routing, and traceable change management with Configured Order Fulfillment (COF).
  • Grow beyond the initial sale with Configured Installed Base management that enables upgrades, service, and compliance across the product lifecycle (CIB).

“Variantum was built to connect engineering, sales, and production into one seamless flow,” said Hanna Kemppainen, CEO of Variantum and now SVP Executive Projects. “By joining Tacton, we can now bring that vision to global scale. Together, we are enabling manufacturers to sell it right, build it right, and deliver it right every time.”

Seamless Intelligence Across the Lifecycle

While Variantum brings lifecycle and fulfillment, Serenytics ensures every stage is optimized by data. The acquisition embeds advanced analytics directly into the platform, giving manufacturers near real-time visibility into buyer behavior, product performance, and lifecycle profitability, without reliance on external BI tools.

“Manufacturers don’t just need more data. They need the right insights at the right time,” added Andersen. “With Serenytics, Tacton provides a single source of truth across the lifecycle, helping teams make faster, smarter, and more profitable decisions.”

“Serenytics was founded to put data directly in the hands of decision-makers,” said Adrien Auclair, founder of Serenytics and now Software Architect at Tacton. “With Tacton, we’re embedding that vision inside one of the most powerful Buyer Engagement Platforms in complex manufacturing.”

Creating the Buyer-Centric Smart Factory

The combined capabilities advance Tacton’s vision of the Buyer-Centric Smart Factory. Recognized as the global leader in CPQ for complex manufacturing, Tacton has already transformed how manufacturers configure complex products and increase revenue. With the addition of Variantum and Serenytics, Tacton can now extend across the entire lifecycle. Manufacturers can now:

  • Gain Control of Product Configurability: Create a single source of truth for configurability across the lifecycle, connected to revisions of the product architecture and bill of materials, with full transparency in Sales and Order Fulfillment.
  • Sell Faster: Empower sales teams to deliver accurate, compelling proposals without engineering bottlenecks. Bring solutions to life with advanced visualization that allows buyers to experience products virtually in their own environment.
  • Deliver a Better Buyer Experience: Put customer needs first by creating a simple, intuitive, and engaging buying process that strengthens trust and loyalty.
  • Build Profitably: Ensure every order is manufacturable and margin-protected through a seamless flow of validated configuration data.
  • Deliver Beyond the Sale: Unlock service, upgrades, and lifecycle insights for stronger customer relationships.
  • Decide Smarter: Use embedded analytics to turn lifecycle data into actions and accelerate growth.

Under the leadership of newly appointed CEO Klaus Andersen, Tacton is executing a clear strategy to expand beyond CPQ and lead the industry in not only buyer engagement but also in smart factory. Andersen is accelerating innovation by uniting sales, engineering, order fulfillment, and aftermarket into one platform. These strategic investments position Tacton as the only provider delivering an end-to-end Buyer Engagement Platform that connects every stage of the lifecycle and powers it with real-time insights.

“These acquisitions mark a bold step forward,” concluded Andersen. “Our customers have told us they need more than CPQ. They need a connected flow that ensures what is sold can be built, delivered, and serviced profitably. The Buyer-Centric Smart Factory is our answer — a complete platform where every step is aligned, every margin protected, and every outcome powered by data.”

Learn more about how Tacton is redefining buyer engagement with Variantum and Serenytics.

About Variantum

Founded in 2005 and headquartered in Espoo, Finland, Variantum specializes in configuration solutions for complex manufacturing. Its product portfolio includes Configuration Lifecycle Management (CLM), Configurable Order Fulfillment (COF), and Configured Installed Base Management (CIB). Variantum has served global manufacturers such as KONE, Abloy, and Chiller, helping them connect engineering, sales, and production processes into one seamless flow.

About Serenytics

Serenytics is a SaaS data visualization platform that enables advanced dashboard creation in just a few clicks, with no need for developers. It supports connecting data via CSV, API, SQL, or data warehouses, handling small to very large datasets. Founded in France in 2015, Serenytics makes complex data usable and shareable across teams and systems.

About Tacton

Tacton is a leading SaaS company, redefining CPQ buyer engagement for manufacturers of complex configurable products. By streamlining the buyer journey, Tacton empowers manufacturers to accelerate go-to-market strategies, increase sales, and build brand loyalty. Trusted since 1998 by global leaders such as ABB, Daimler, MAN, Scania, Siemens, Xylem, and Yaskawa, Tacton continues to drive innovation in manufacturing. The company is co-headquartered in Chicago and Stockholm, with regional offices in Karlsruhe, Warsaw, Helsinki, Paris and Tokyo. Learn more at tacton.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251006237381/en/

Contacts

Marketbridge
Gail Scibelli
gscibelli@marketbridge.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye